Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + Low-Dose Dexamethasone in RRMM with Renal Impairment
NCT02045017Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2014
- Primary completion
- Jan 2017
- Modality
- Molecular Glues
- Countries
- 8
01
Overview
A Phase 2 trial of pomalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Feb 2014; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02045017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045017.